MedRx Co., Ltd (TYO:4586)
Japan
· Delayed Price · Currency is JPY 108.00
+9.00 (9.09%)
Mar 10, 2026, 1:34 PM JST
MedRx Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 1,754 | 1,977 | 1,720 | 994 | 1,703 | Upgrade
|
| Cash & Short-Term Investments | 1,754 | 1,977 | 1,720 | 994 | 1,703 | Upgrade
|
| Cash Growth | -11.28% | 14.94% | 73.04% | -41.63% | -6.02% | Upgrade
|
| Other Receivables | 12 | 44 | 33 | 15 | 23 | Upgrade
|
| Receivables | 12 | 44 | 33 | 15 | 23 | Upgrade
|
| Inventory | 16 | 10 | 10 | 8 | 11 | Upgrade
|
| Other Current Assets | 42 | 41 | 22 | 70 | 17 | Upgrade
|
| Total Current Assets | 1,824 | 2,072 | 1,785 | 1,087 | 1,754 | Upgrade
|
| Property, Plant & Equipment | 192 | 123 | 181 | 226 | 270 | Upgrade
|
| Long-Term Investments | 140 | 79 | 85 | 84 | 83 | Upgrade
|
| Other Long-Term Assets | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Total Assets | 2,157 | 2,275 | 2,052 | 1,398 | 2,108 | Upgrade
|
| Current Income Taxes Payable | 75 | 103 | 98 | 156 | 124 | Upgrade
|
| Other Current Liabilities | 2 | 2 | 1 | 2 | 1 | Upgrade
|
| Total Current Liabilities | 77 | 105 | 99 | 158 | 125 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 31 | - | 4 | 5 | 5 | Upgrade
|
| Other Long-Term Liabilities | 2 | 2 | 26 | 24 | 23 | Upgrade
|
| Total Liabilities | 110 | 107 | 129 | 187 | 153 | Upgrade
|
| Common Stock | 450 | 580 | 847 | 227 | 7,803 | Upgrade
|
| Additional Paid-In Capital | 2,358 | 2,314 | 1,916 | 3,063 | 7,372 | Upgrade
|
| Retained Earnings | -898 | -787 | -915 | -2,150 | -13,279 | Upgrade
|
| Comprehensive Income & Other | 137 | 61 | 75 | 71 | 59 | Upgrade
|
| Shareholders' Equity | 2,047 | 2,168 | 1,923 | 1,211 | 1,955 | Upgrade
|
| Total Liabilities & Equity | 2,157 | 2,275 | 2,052 | 1,398 | 2,108 | Upgrade
|
| Net Cash (Debt) | 1,754 | 1,977 | 1,720 | 994 | 1,703 | Upgrade
|
| Net Cash Growth | -11.28% | 14.94% | 73.04% | -41.63% | -3.35% | Upgrade
|
| Net Cash Per Share | 32.64 | 45.48 | 49.46 | 39.19 | 79.74 | Upgrade
|
| Filing Date Shares Outstanding | 59.43 | 47.5 | 38.48 | 30.7 | 24.6 | Upgrade
|
| Total Common Shares Outstanding | 59.43 | 47.5 | 38.37 | 28.22 | 24.6 | Upgrade
|
| Working Capital | 1,747 | 1,967 | 1,686 | 929 | 1,629 | Upgrade
|
| Book Value Per Share | 34.45 | 45.65 | 50.12 | 42.91 | 79.49 | Upgrade
|
| Tangible Book Value | 2,047 | 2,168 | 1,923 | 1,211 | 1,955 | Upgrade
|
| Tangible Book Value Per Share | 34.45 | 45.65 | 50.12 | 42.91 | 79.49 | Upgrade
|
| Order Backlog | - | - | - | 2 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.